Oxford Genome Sciences Changes Name to Reflect Rx Focus | GenomeWeb
NEW YORK (GenomeWeb News) – Oxford Genome Sciences today said that it has changed its name to Oxford BioTherapeutics.
The Oxford, UK-based firm said the name change comes as it focuses its efforts on the development of its pipeline of antibody-based cancer therapeutics. The firm also has a collaboration with diagnostics firm Biosite to develop companion diagnostics for its cancer therapeutics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.